Drug Profile


Alternative Names: Anti-PD-1 monoclonal antibody - Merck; Humanised monoclonal IgG4 antibody against PD-1 - Merck; Keytruda; Lambrolizumab; MK-3475; SCH-900475

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co; The Leukemia & Lymphoma Society
  • Developer Aduro BioTech; Amgen; BerGenBio; Big Ten Cancer Research Consortium; BioLineRx; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; DNAtrix; Eisai Co Ltd; Eli Lilly; Emory University; Exelixis; Fox Chase Cancer Center; Genexine; Hoosier Cancer Research Network; Icahn School of Medicine at Mount Sinai; ImmunoGen; Incyte Corporation; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Northwestern University; NYU Langone Medical Center; Oslo University Hospital; Plexxikon; Providence Health & Services; Sarcoma Alliance for Research through Collaboration; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; TG Therapeutics Inc; University of Alabama; University of Birmingham; University of California at San Francisco; University of California, San Diego; University of Pittsburgh; Verastem; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Programmed cell death 1 ligand 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Preregistration Gastric cancer
  • Phase III Breast cancer; Hepatocellular carcinoma; Liver cancer; Multiple myeloma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Adenocarcinoma; Bladder cancer; Bone cancer; Brain metastases; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Inflammatory breast cancer; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Penile cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Soft tissue sarcoma; Squamous cell cancer; Thymoma; Thyroid cancer
  • Phase I/II Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase I Gastrointestinal cancer; Haematological malignancies
  • Preclinical Human papillomavirus infections

Most Recent Events

  • 11 Aug 2017 Dana-Farber Cancer Institute plans a phase I trial for Solid tumours(Late-stage disease, Combination therapy) in USA (NCT03239145)
  • 11 Aug 2017 University of Chicago plans a phase II trial for Head and neck cancer (Second-line therapy or greater, Combination therapy) in USA(NCT03238638)
  • 04 Aug 2017 Merck initiates enrolment in a phase II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03220477)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top